Deep Brain Stimulation in Parkinson's Disease Market - Global Outlook and Forecast 2021-2027

April 2021 | 91 pages | ID: DB62EABD8148EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Deep Brain Stimulation in Parkinson's Disease in Global, including the following market information:

Global Deep Brain Stimulation in Parkinson's Disease Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global Deep Brain Stimulation in Parkinson's Disease market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Deep Brain Stimulation in Parkinson's Disease companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Deep Brain Stimulation in Parkinson's Disease Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global Deep Brain Stimulation in Parkinson's Disease Market Segment Percentages, By Type, 2020 (%)

• Dual Channel Deep brain Stimulator
• Single Channel Deep brain Stimulator

China Deep Brain Stimulation in Parkinson's Disease Market, By Application, 2016-2021, 2022-2027 ($ millions)

China Deep Brain Stimulation in Parkinson's Disease Market Segment Percentages, By Application, 2020 (%)

• Hospitals
• Neurology Clinics
• Research Centers

Global Deep Brain Stimulation in Parkinson's Disease Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global Deep Brain Stimulation in Parkinson's Disease Market Segment Percentages, By Region and Country, 2020 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Deep Brain Stimulation in Parkinson's Disease Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total Deep Brain Stimulation in Parkinson's Disease Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:

• Abbott
• Aleva Neurotherapeutics SA
• Beijing PINS Medical Co
• Boston Scientific Corporation
• Functional Neuromodulation Ltd
• Medtronic
• Neuronetics Inc.
• NeuroPace Inc.
• Nevro Corporation

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Anti-Asthmatics and COPD Drugs Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Anti-Asthmatics and COPD Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL ANTI-ASTHMATICS AND COPD DRUGS OVERALL MARKET SIZE

2.1 Global Anti-Asthmatics and COPD Drugs Market Size: 2021 VS 2027
2.2 Global Anti-Asthmatics and COPD Drugs Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Anti-Asthmatics and COPD Drugs Players in Global Market
3.2 Top Global Anti-Asthmatics and COPD Drugs Companies Ranked by Revenue
3.3 Global Anti-Asthmatics and COPD Drugs Revenue by Companies
3.4 Top 3 and Top 5 Anti-Asthmatics and COPD Drugs Companies in Global Market, by Revenue in 2020
3.5 Global Companies Anti-Asthmatics and COPD Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Anti-Asthmatics and COPD Drugs Players in Global Market
  3.6.1 List of Global Tier 1 Anti-Asthmatics and COPD Drugs Companies
  3.6.2 List of Global Tier 2 and Tier 3 Anti-Asthmatics and COPD Drugs Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global Anti-Asthmatics and COPD Drugs Market Size Markets, 2021 & 2027
  4.1.2 Anti-inflammatory Drugs
  4.1.3 Monoclonal Antibodies
  4.1.4 Combination Drugs
4.2 By Type - Global Anti-Asthmatics and COPD Drugs Revenue & Forecasts
  4.2.1 By Type - Global Anti-Asthmatics and COPD Drugs Revenue, 2016-2021
  4.2.2 By Type - Global Anti-Asthmatics and COPD Drugs Revenue, 2022-2027
  4.2.3 By Type - Global Anti-Asthmatics and COPD Drugs Revenue Market Share, 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Anti-Asthmatics and COPD Drugs Market Size, 2021 & 2027
  5.1.2 Hospital Pharmacies
  5.1.3 Retail Pharmacies
  5.1.4 Online Pharmacies
5.2 By Application - Global Anti-Asthmatics and COPD Drugs Revenue & Forecasts
  5.2.1 By Application - Global Anti-Asthmatics and COPD Drugs Revenue, 2016-2021
  5.2.2 By Application - Global Anti-Asthmatics and COPD Drugs Revenue, 2022-2027
  5.2.3 By Application - Global Anti-Asthmatics and COPD Drugs Revenue Market Share, 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global Anti-Asthmatics and COPD Drugs Market Size, 2021 & 2027
6.2 By Region - Global Anti-Asthmatics and COPD Drugs Revenue & Forecasts
  6.2.1 By Region - Global Anti-Asthmatics and COPD Drugs Revenue, 2016-2021
  6.2.2 By Region - Global Anti-Asthmatics and COPD Drugs Revenue, 2022-2027
  6.2.3 By Region - Global Anti-Asthmatics and COPD Drugs Revenue Market Share, 2016-2027
6.3 North America
  6.3.1 By Country - North America Anti-Asthmatics and COPD Drugs Revenue, 2016-2027
  6.3.2 US Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
  6.3.3 Canada Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
  6.3.4 Mexico Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
6.4 Europe
  6.4.1 By Country - Europe Anti-Asthmatics and COPD Drugs Revenue, 2016-2027
  6.4.2 Germany Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
  6.4.3 France Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
  6.4.4 U.K. Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
  6.4.5 Italy Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
  6.4.6 Russia Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
  6.4.7 Nordic Countries Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
  6.4.8 Benelux Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
6.5 Asia
  6.5.1 By Region - Asia Anti-Asthmatics and COPD Drugs Revenue, 2016-2027
  6.5.2 China Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
  6.5.3 Japan Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
  6.5.4 South Korea Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
  6.5.5 Southeast Asia Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
  6.5.6 India Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
6.6 South America
  6.6.1 By Country - South America Anti-Asthmatics and COPD Drugs Revenue, 2016-2027
  6.6.2 Brazil Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
  6.6.3 Argentina Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Anti-Asthmatics and COPD Drugs Revenue, 2016-2027
  6.7.2 Turkey Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
  6.7.3 Israel Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
  6.7.4 Saudi Arabia Anti-Asthmatics and COPD Drugs Market Size, 2016-2027
  6.7.5 UAE Anti-Asthmatics and COPD Drugs Market Size, 2016-2027

7 PLAYERS PROFILES

7.1 Novartis AG
  7.1.1 Novartis AG Corporate Summary
  7.1.2 Novartis AG Business Overview
  7.1.3 Novartis AG Anti-Asthmatics and COPD Drugs Major Product Offerings
  7.1.4 Novartis AG Anti-Asthmatics and COPD Drugs Revenue in Global (2016-2021)
  7.1.5 Novartis AG Key News
7.2 Merck & Co
  7.2.1 Merck & Co Corporate Summary
  7.2.2 Merck & Co Business Overview
  7.2.3 Merck & Co Anti-Asthmatics and COPD Drugs Major Product Offerings
  7.2.4 Merck & Co Anti-Asthmatics and COPD Drugs Revenue in Global (2016-2021)
  7.2.5 Merck & Co Key News
7.3 GlaxoSmithKline
  7.3.1 GlaxoSmithKline Corporate Summary
  7.3.2 GlaxoSmithKline Business Overview
  7.3.3 GlaxoSmithKline Anti-Asthmatics and COPD Drugs Major Product Offerings
  7.3.4 GlaxoSmithKline Anti-Asthmatics and COPD Drugs Revenue in Global (2016-2021)
  7.3.5 GlaxoSmithKline Key News
7.4 Boehringer Ingelheim Gmbh
  7.4.1 Boehringer Ingelheim Gmbh Corporate Summary
  7.4.2 Boehringer Ingelheim Gmbh Business Overview
  7.4.3 Boehringer Ingelheim Gmbh Anti-Asthmatics and COPD Drugs Major Product Offerings
  7.4.4 Boehringer Ingelheim Gmbh Anti-Asthmatics and COPD Drugs Revenue in Global (2016-2021)
  7.4.5 Boehringer Ingelheim Gmbh Key News
7.5 AstraZeneca
  7.5.1 AstraZeneca Corporate Summary
  7.5.2 AstraZeneca Business Overview
  7.5.3 AstraZeneca Anti-Asthmatics and COPD Drugs Major Product Offerings
  7.5.4 AstraZeneca Anti-Asthmatics and COPD Drugs Revenue in Global (2016-2021)
  7.5.5 AstraZeneca Key News
7.6 Roche
  7.6.1 Roche Corporate Summary
  7.6.2 Roche Business Overview
  7.6.3 Roche Anti-Asthmatics and COPD Drugs Major Product Offerings
  7.6.4 Roche Anti-Asthmatics and COPD Drugs Revenue in Global (2016-2021)
  7.6.5 Roche Key News
7.7 Teva Pharmaceutical
  7.7.1 Teva Pharmaceutical Corporate Summary
  7.7.2 Teva Pharmaceutical Business Overview
  7.7.3 Teva Pharmaceutical Anti-Asthmatics and COPD Drugs Major Product Offerings
  7.4.4 Teva Pharmaceutical Anti-Asthmatics and COPD Drugs Revenue in Global (2016-2021)
  7.7.5 Teva Pharmaceutical Key News
7.8 Vectura
  7.8.1 Vectura Corporate Summary
  7.8.2 Vectura Business Overview
  7.8.3 Vectura Anti-Asthmatics and COPD Drugs Major Product Offerings
  7.8.4 Vectura Anti-Asthmatics and COPD Drugs Revenue in Global (2016-2021)
  7.8.5 Vectura Key News
7.9 Pfizer
  7.9.1 Pfizer Corporate Summary
  7.9.2 Pfizer Business Overview
  7.9.3 Pfizer Anti-Asthmatics and COPD Drugs Major Product Offerings
  7.9.4 Pfizer Anti-Asthmatics and COPD Drugs Revenue in Global (2016-2021)
  7.9.5 Pfizer Key News
7.10 Abbott
  7.10.1 Abbott Corporate Summary
  7.10.2 Abbott Business Overview
  7.10.3 Abbott Anti-Asthmatics and COPD Drugs Major Product Offerings
  7.10.4 Abbott Anti-Asthmatics and COPD Drugs Revenue in Global (2016-2021)
  7.10.5 Abbott Key News
7.11 Mylan
  7.11.1 Mylan Corporate Summary
  7.11.2 Mylan Business Overview
  7.11.3 Mylan Anti-Asthmatics and COPD Drugs Major Product Offerings
  7.11.4 Mylan Anti-Asthmatics and COPD Drugs Revenue in Global (2016-2021)
  7.11.5 Mylan Key News
7.12 Allergan
  7.12.1 Allergan Corporate Summary
  7.12.2 Allergan Business Overview
  7.12.3 Allergan Anti-Asthmatics and COPD Drugs Major Product Offerings
  7.12.4 Allergan Anti-Asthmatics and COPD Drugs Revenue in Global (2016-2021)
  7.12.5 Allergan Key News
7.13 Cipla
  7.13.1 Cipla Corporate Summary
  7.13.2 Cipla Business Overview
  7.13.3 Cipla Anti-Asthmatics and COPD Drugs Major Product Offerings
  7.13.4 Cipla Anti-Asthmatics and COPD Drugs Revenue in Global (2016-2021)
  7.13.5 Cipla Key News
7.14 Akorn
  7.14.1 Akorn Corporate Summary
  7.14.2 Akorn Business Overview
  7.14.3 Akorn Anti-Asthmatics and COPD Drugs Major Product Offerings
  7.14.4 Akorn Anti-Asthmatics and COPD Drugs Revenue in Global (2016-2021)
  7.14.5 Akorn Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Deep Brain Stimulation in Parkinson's Disease Market Opportunities & Trends in Global Market
Table 2. Deep Brain Stimulation in Parkinson's Disease Market Drivers in Global Market
Table 3. Deep Brain Stimulation in Parkinson's Disease Market Restraints in Global Market
Table 4. Key Players of Deep Brain Stimulation in Parkinson's Disease in Global Market
Table 5. Top Deep Brain Stimulation in Parkinson's Disease Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Deep Brain Stimulation in Parkinson's Disease Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Deep Brain Stimulation in Parkinson's Disease Revenue Share by Companies, 2016-2021
Table 8. Global Companies Deep Brain Stimulation in Parkinson's Disease Product Type
Table 9. List of Global Tier 1 Deep Brain Stimulation in Parkinson's Disease Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Deep Brain Stimulation in Parkinson's Disease Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Deep Brain Stimulation in Parkinson's Disease Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Deep Brain Stimulation in Parkinson's Disease Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Deep Brain Stimulation in Parkinson's Disease Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Deep Brain Stimulation in Parkinson's Disease Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Deep Brain Stimulation in Parkinson's Disease Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Deep Brain Stimulation in Parkinson's Disease Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2022-2027
Table 30. Abbott Corporate Summary
Table 31. Abbott Deep Brain Stimulation in Parkinson's Disease Product Offerings
Table 32. Abbott Deep Brain Stimulation in Parkinson's Disease Revenue (US$, Mn), (2016-2021)
Table 33. Aleva Neurotherapeutics SA Corporate Summary
Table 34. Aleva Neurotherapeutics SA Deep Brain Stimulation in Parkinson's Disease Product Offerings
Table 35. Aleva Neurotherapeutics SA Deep Brain Stimulation in Parkinson's Disease Revenue (US$, Mn), (2016-2021)
Table 36. Beijing PINS Medical Co Corporate Summary
Table 37. Beijing PINS Medical Co Deep Brain Stimulation in Parkinson's Disease Product Offerings
Table 38. Beijing PINS Medical Co Deep Brain Stimulation in Parkinson's Disease Revenue (US$, Mn), (2016-2021)
Table 39. Boston Scientific Corporation Corporate Summary
Table 40. Boston Scientific Corporation Deep Brain Stimulation in Parkinson's Disease Product Offerings
Table 41. Boston Scientific Corporation Deep Brain Stimulation in Parkinson's Disease Revenue (US$, Mn), (2016-2021)
Table 42. Functional Neuromodulation Ltd Corporate Summary
Table 43. Functional Neuromodulation Ltd Deep Brain Stimulation in Parkinson's Disease Product Offerings
Table 44. Functional Neuromodulation Ltd Deep Brain Stimulation in Parkinson's Disease Revenue (US$, Mn), (2016-2021)
Table 45. Medtronic Corporate Summary
Table 46. Medtronic Deep Brain Stimulation in Parkinson's Disease Product Offerings
Table 47. Medtronic Deep Brain Stimulation in Parkinson's Disease Revenue (US$, Mn), (2016-2021)
Table 48. Neuronetics Inc. Corporate Summary
Table 49. Neuronetics Inc. Deep Brain Stimulation in Parkinson's Disease Product Offerings
Table 50. Neuronetics Inc. Deep Brain Stimulation in Parkinson's Disease Revenue (US$, Mn), (2016-2021)
Table 51. NeuroPace Inc. Corporate Summary
Table 52. NeuroPace Inc. Deep Brain Stimulation in Parkinson's Disease Product Offerings
Table 53. NeuroPace Inc. Deep Brain Stimulation in Parkinson's Disease Revenue (US$, Mn), (2016-2021)
Table 54. Nevro Corporation Corporate Summary
Table 55. Nevro Corporation Deep Brain Stimulation in Parkinson's Disease Product Offerings
Table 56. Nevro Corporation Deep Brain Stimulation in Parkinson's Disease Revenue (US$, Mn), (2016-2021)

List Of Figures

LIST OF FIGURES

Figure 1. Deep Brain Stimulation in Parkinson's Disease Segment by Type
Figure 2. Deep Brain Stimulation in Parkinson's Disease Segment by Application
Figure 3. Global Deep Brain Stimulation in Parkinson's Disease Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Deep Brain Stimulation in Parkinson's Disease Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Deep Brain Stimulation in Parkinson's Disease Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Deep Brain Stimulation in Parkinson's Disease Revenue in 2020
Figure 8. By Type - Global Deep Brain Stimulation in Parkinson's Disease Revenue Market Share, 2016-2027
Figure 9. By Application - Global Deep Brain Stimulation in Parkinson's Disease Revenue Market Share, 2016-2027
Figure 10. By Region - Global Deep Brain Stimulation in Parkinson's Disease Revenue Market Share, 2016-2027
Figure 11. By Country - North America Deep Brain Stimulation in Parkinson's Disease Revenue Market Share, 2016-2027
Figure 12. US Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Deep Brain Stimulation in Parkinson's Disease Revenue Market Share, 2016-2027
Figure 16. Germany Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 17. France Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Deep Brain Stimulation in Parkinson's Disease Revenue Market Share, 2016-2027
Figure 24. China Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 28. India Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Deep Brain Stimulation in Parkinson's Disease Revenue Market Share, 2016-2027
Figure 30. Brazil Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Deep Brain Stimulation in Parkinson's Disease Revenue Market Share, 2016-2027
Figure 33. Turkey Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Deep Brain Stimulation in Parkinson's Disease Revenue, (US$, Mn), 2016-2027
Figure 37. Abbott Deep Brain Stimulation in Parkinson's Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Aleva Neurotherapeutics SA Deep Brain Stimulation in Parkinson's Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Beijing PINS Medical Co Deep Brain Stimulation in Parkinson's Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. Boston Scientific Corporation Deep Brain Stimulation in Parkinson's Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Functional Neuromodulation Ltd Deep Brain Stimulation in Parkinson's Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Medtronic Deep Brain Stimulation in Parkinson's Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. Neuronetics Inc. Deep Brain Stimulation in Parkinson's Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. NeuroPace Inc. Deep Brain Stimulation in Parkinson's Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)